No profile data available.
OS Therapies Incorporated (OSTX) is a healthcare company in the additional cancer treatment drugs industry, based in Grasonville, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$28.75 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $75.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OS Therapies reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$75.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include NeOnc Technologies Holdings, Inc. (NTHI), Sutro Biopharma, Inc. (STRO), Instil Bio, Inc. (TIL), Maia Biotechnology, Inc. (MAIA).